Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D 2 Receptors: a PET Study in Schizophrenia
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Antipsychotic medications improve psychosis but often induce a state of dysphoria in patients. Blockade of the dopamine D(2) receptors, which is thought to mediate their efficacy, has also been implicated in producing this adverse subjective experience. The authors present the first double-blind controlled study to examine the relationship between striatal and extrastriatal dopamine D(2) receptor binding potential and occupancy values and adverse subjective experience. METHOD: Patients with recent-onset psychosis (N=12) were randomly assigned to low or high doses of olanzapine or risperidone. Subjective experiences, motor side effects, and striatal and extrastriatal dopamine D(2) receptors (determined with [(11)C]raclopride and [(11)C]FLB 457 PET scans, respectively) were evaluated after 2 weeks of continuous antipsychotic treatment. RESULTS: Higher dopamine D(2) receptor occupancy and binding potentials in the striatal (dorsal and ventral), temporal, and insular regions were associated with subjective experience. The finding was confirmed with two convergent methods of analysis (region-of-interest and voxel-based statistics), and the same relationship was observed using two different dopamine receptor measures (observed binding potential values and age- and sex-corrected occupancy values). CONCLUSIONS: Higher D(2) receptor occupancy is associated with negative subjective experience in patients taking risperidone or olanzapine. These negative subjective effects may be related to the high discontinuation rates seen in usual practice. Understanding the neurobiological mechanism of these negative subjective experiences and developing antipsychotics with novel (i.e., non D(2)) mechanisms may be critical in improving the treatment of psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine, learning and motivation.
Wise, R. A. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1406 · Cited by 3,379 · cited 1×
“The ventral portion of the striatum (which is thought to be the analogue of the nucleus accumbens in animals) is directly implicated in reward and motivation (15, 31) and is key to many of the nonmotor actions of antipsychotics in animals (i.”
Mayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A., Silva, J. A., Tekell, J. L., Martin, C. C., Lancaster, J. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.675 · Cited by 2,416
Wise, R. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00965-0 · Cited by 881 · cited 1×
“The ventral portion of the striatum (which is thought to be the analogue of the nucleus accumbens in animals) is directly implicated in reward and motivation (15, 31) and is key to many of the nonmotor actions of antipsychotics in animals (i.”
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria
Drevets, W. C., Gautier, C., Price, J. C., Kupfer, D. J., Kinahan, P. E., Grace, A. A., Price, J. L., & Mathis, C. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01038-6 · Cited by 706 · cited 1×
“For example, euphoric responses elicited by amphetamine were inversely correlated with change in ventral striatum binding potential in healthy volunteers (35).”
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638 · cited 1×
“Antipsychotic medications have been the first-line treatment for psychotic disorders for nearly half a century (1).”
Self-citationAlcohol promotes dopamine release in the human nucleus accumbens
Boileau, I., Assaad, J., Pihl, R. O., Benkelfat, C., Leyton, M., Diksic, M., Tremblay, R. E., & Dagher, A. (2003) · Synapse · doi:10.1002/syn.10226 · Cited by 591
Human feelings: why are some more aware than others?
Craig, A. D. (. (2004) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2004.04.004 · Cited by 445 · cited 1×
“In addition, the insular cortex, which has modest concentrations of dopamine D2 receptors as measured in autoradiography studies in human brains (36), has been implicated in the integration of internal states and has been associated with feelings of sadness (37) and the subjective awareness of internal feelings (38).”
Dopamine: a key regulator to adapt action, emotion, motivation and cognition
Nieoullon, A., & Coquerel, A. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200312002-00002 · Cited by 315 · cited 2×
“This is not surprising since the dopamine action has been associated with cognition, motivation, emotion, and action (12).”
Cited by
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Self-citationGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis
Carlezon, W. A., & Thomas, M. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.075 · Cited by 561
Goodwin, G., & Consensus Group of the British Association for Psychopharmacology (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102919 · Cited by 444
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Metadata
- Authors
- Mizrahi, R., Rusjan, P., Agid, O., Graff, A., Mamo, D. C., Zipursky, R. B., & Kapur, S.
- Venue
- American Journal of Psychiatry
- Published
- 2007-04
- Volume
- 164
- Issue
- 4
- Pages
- 630-637
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2067024769
- Cited by
- 111
- References
- 8
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.